These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 18343273

  • 1. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 17; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A, Edmunds WJ.
    Vaccine; 2004 Oct 22; 22(31-32):4203-14. PubMed ID: 15474710
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C, Reinert RR, von der Schulenburg JM.
    Eur J Health Econ; 2009 Feb 22; 10(1):25-38. PubMed ID: 18379830
    [Abstract] [Full Text] [Related]

  • 6. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ.
    Vaccine; 2007 May 04; 25(18):3669-78. PubMed ID: 17360082
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.
    Vaccine; 2004 Mar 12; 22(9-10):1138-49. PubMed ID: 15003641
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.
    Vaccine; 2011 Sep 02; 29(38):6686-94. PubMed ID: 21745516
    [Abstract] [Full Text] [Related]

  • 11. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA, Berg S, Hemlin C, Jokinen I.
    Vaccine; 2009 Mar 04; 27(10):1601-8. PubMed ID: 19146905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.
    Vaccine; 2007 Jul 20; 25(29):5390-8. PubMed ID: 17583392
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.
    Pediatr Infect Dis J; 2006 Jun 20; 25(6):494-501. PubMed ID: 16732146
    [Abstract] [Full Text] [Related]

  • 15. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D.
    Value Health; 2011 Jun 20; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.
    Scand J Infect Dis; 2008 Jun 20; 40(9):721-9. PubMed ID: 18712627
    [Abstract] [Full Text] [Related]

  • 17. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2005 Sep 16; 54(36):893-7. PubMed ID: 16163262
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
    Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.
    Vaccine; 2010 Nov 10; 28(48):7634-43. PubMed ID: 20883739
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.
    BMJ; 2010 Jun 02; 340():c2509. PubMed ID: 20519267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.